An immunohistochemical study on transforming growth factor-β in the skin of systemic sclerosis patients with reference to the histopathologic stage

European Journal of Dermatology

Volumn 6, Issue 7, 1996, Pages 482-485

  Sato, Matoka ^a   Ishikawa, Osamu ^a   Miyachi, Yoshiki ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; Systemic sclerosis; Transforming growth factor

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; SYSTEMIC SCLEROSIS;

EID: 0029902233     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. LeRoy EC, Smith EA Kahaleh MB, Trojanowska M, Silver RM. A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor β the answer? Arthritis Rheum 1989; 32: 817-25.
2. Sfikakis PP, McCune BK, Tsokos M, Aroni K, Vayiopoulos G, Tsokos GC. Immunohistological demonstration of transforming growth factor-β in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 1993; 69: 199-204.
3. Gay S, Jones Jr RE, Huang G, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989; 92: 301-3.
4. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaren R, Black C. Immunocytochemical localization and serologic detection of transforming growth factor β1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994; 37: 278-88.
5. Gruschwtiz M, Müller PU, Sepp N, Hofer E, Fontana A, Wick G. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990; 94: 197-203.
6. Peltonen J, Kähäri L, Jaakkola S, Kähäri V-M, Varga J, Uitto J, Jimenez SA. Evaluation of transforming growth factor β and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization. J Invest Dermatol 1990; 94: 365-71.
7. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
8. Ishikawa O, Ishikawa H. Macrophage infiltration in the skin of patients with systemic sclerosis. J Rheumatol 1992; 19: 1202-6.
9. Wahl SM. The role of lymphokines in fibrosis. In: Fleischmajer R, Olsen B, Ktihn K, eds. Biology, chemistry and pathology of collagen. New York: The New York Academy of Science, 1986: 404-29.
10. 1 on extracellular matrix gene expression in human dermal fibroblasts. Biochem Biophys Res Commun 1990; 169: 232-8.
11. Mauch C, Eckes B, Hunzelmann N, Oono T, Kozlowska E, Krieg T. Control of fibrosis in systemic scleroderma. J Invest Dermatol 1993; 100: 92S-6S.
12. Gronwald RG, Seifert RA, Bowen-Pope DF. Differential regulation of expression of two platelet-derived growth factor receptor subunits by transforming growth factor-beta. J Biol Chem 1989; 246: 8120-5.
13. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, Takehara K. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995; 105: 280-4.
14. Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 1993; 4: 637-45.
15. Levesque H, Baudot N, Delpech B, Vayssairat M, Gancel A, Lauret P. Courtois H. Clinical correlations and prognosis based on hyaluronic acid serum levels in patients with progressive systemic sclerosis. Br J Dermatol 1991; 124: 423-8.
16. Patrick MR, Kirkham BW, Graham M, Harrision LC. Circulating interleukin 1β and soluble interleukin 2 receptor: evaluation as markers of disease activity in scleroderma. J Rheumatol 1995; 22: 654-8.
17. Zachariae H, Bjerring P, Halkier-Sørensen I, Heickendorff L, Søndergaard K. Skin scoring in systemic sclerosis: a modification-relation to subtypes and the aminoterminal propeptide of type III procollagen (PIIINP). Acta Derm Venereol (Stockh) 1994; 74: 444-6.